Curevac N.V. Stock
Price
Target price
€2.96
€2.96
-0.070%
-0.002
-0.070%
€504.00
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Curevac N.V. Stock
With only a change of -€0.002 (-0.070%) the Curevac N.V. price is nearly unchanged from yesterday.
Our community is currently high on Curevac N.V. with 4 Buy predictions and 0 Sell predictions.
With a target price of 504 € there is potential for a 16938.54% increase which would mean more than doubling the current price of 2.96 € for Curevac N.V..
Our community identified positive and negative aspects for Curevac N.V. stock for the coming years. 19 users see the criterium "Worthwhile Investment for the next years" as a plus for the Curevac N.V. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Curevac N.V. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
News
EQS-News: CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
EQS-News: CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
EQS-News: CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
EQS-News: CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
EQS-News: CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
EQS-News: CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress